Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.32 per share a year ago.
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $1.27 per share a year ago.
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.29 per share a year ago.
Opus Genetics, Inc. (IRD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Opus Genetics, Inc. - Special Call
Opus Genetics, Inc. - Special Call Company Participants Jenny Kobin George Magrath - CEO & Director Sally Tucker Conference Call Participants Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Dev Prasad - Lucid Capital Markets, LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Boris Peaker James Molloy - Alliance Global Partners, Research Division Madison Wynne El-Saadi - B.
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.3 per share a year ago.
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.29 per share a year ago.
Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline
Opus Genetics, Inc. (IRD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to earnings of $0.25 per share a year ago.
